Cardiff Oncology, Inc.
CRDF · XNASCIK 1213037fmd_1A9JVZFW91VTHSC9M2TZQDPEB9Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Aug 04, 1999 to Sep 30, 2026, 74 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Cost of revenue | 2 | 2 | 1 | 0 | – | – | – | – | – | – |
| Net interest income | (1) | – | – | – | – | – | – | – | – | – |
| Gross profit | (1) | (1) | (0) | 0 | – | – | – | – | – | – |
| Research and development | 15 | 8 | 8 | 11 | 11 | 17 | 27 | 33 | 37 | 35 |
| Selling, general and administrative | 23 | 14 | 8 | 6 | 8 | 12 | 13 | 13 | 12 | 14 |
| Total operating expenses | 41 | 26 | 17 | 17 | 19 | 29 | 40 | 46 | 49 | 50 |
| Operating income | (40) | (26) | (17) | (17) | (19) | (29) | (40) | (45) | (49) | (49) |
| Interest expense | 2 | 1 | 0 | 0 | 0 | 0 | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 3 | 3 |
| Other non-operating income (expense) | – | – | – | – | (0) | 1 | 1 | 4 | 3 | 3 |
| Income before taxes | – | – | – | – | – | – | – | – | (45) | (46) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | (45) | (46) |
| Net income | (39) | (25) | (16) | (16) | (19) | (28) | (39) | (41) | (45) | (46) |
| Net income to common shareholders | (39) | (25) | (19) | (17) | (23) | (28) | (39) | (41) | (45) | (46) |